BioLineRX
BLRX
28 hedge funds and large institutions have $1.36M invested in BioLineRX in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
8% more funds holding
Funds holding: 26 → 28 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
32% less capital invested
Capital invested by funds: $1.99M → $1.36M (-$627K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.6K |
| 2 |
VF
Virtu Financial
New York
|
+$21.7K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$20.5K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$11.8K |
| 5 |
Citigroup
New York
|
+$4.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$96K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$60K |
| 3 |
Renaissance Technologies
New York
|
-$30K |
| 4 |
Morgan Stanley
New York
|
-$26.9K |
| 5 |
LPL Financial
San Diego,
California
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
26
Steward Partners Investment Advisory
New York
| $1K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $1K | +$1K | +18 | New |
|
|
AWM
28
Apollon Wealth Management
Mount Pleasant,
South Carolina
| – | -$96K | -1,410 | Closed |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$60K | -875 | Closed |
|
|
SCA
30
Sandy Cove Advisors
Hingham,
Massachusetts
| – | -$6K | -90 | Closed |
|
|
PFS
31
Prospera Financial Services
Dallas,
Texas
| – | -$2K | -24 | Closed |
|
BLRX Hedge Fund Activity: Q2 2022 in Review
28 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2022, worth a combined $1.36M — down 32% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BLRX positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.6K. The largest seller was Apollon Wealth Management, exiting entirely with an estimated $96K sold.
- 28 institutional investors held BioLineRX (BLRX) as of Q2 2022, up from 26 in Q1 2022.
- Funds reported $1.36M of BioLineRX stock for Q2 2022, down 32% quarter-over-quarter.
- 6 funds opened new BioLineRX positions in Q2 2022 and 4 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q2 2022 was Citadel Advisors, an estimated $31.6K added.
- The largest BioLineRX seller in Q2 2022 was Apollon Wealth Management, an estimated $96K sold.
Based on aggregated 13F filings for Q2 2022.